TABLE 1

SULT specificity, nonspecific protein binding, and sulfation clearance obtained in liver and intestinal cytosol for quercetin, raloxifene, salbutamol, and troglitazone

Drug	Major SULT Specificity^{^a}	Predicted fu_inc at 1.5 mg/ml^{^b}	Experimentally Derived fu_inc (1.5 mg/ml HLC)	Unbound CL_int,SULT^{^c}
Drug	Major SULT Specificity^{^a}	Predicted fu_inc at 1.5 mg/ml^{^b}	Experimentally Derived fu_inc (1.5 mg/ml HLC)	HLC	HIC
				μl · min⁻¹ · mg⁻¹
Quercetin	SULT1E1, SULT1A1	0.86	N.D.	141 ± 27	186 ± 20
Raloxifene	SULT1E1	0.03	0.14	45 ± 26	41 ± 8
Salbutamol	SULT1A3	0.84	0.59	8.7 ± 4.4	8.0 ± 3.3
Troglitazone	SULT1E1, SULT1A1	0.05	0.23	36 ± 14	57 ± 37

N.D., no experimental value could be determined because of compound degradation during equilibrium dialysis.
↵a References in supplemental data.
↵b Data predicted using Hallifax and Houston (2006) algorithm.
↵c Data represent the mean ± S.D. of three separate experiments using the same pool of HLC or HIC.